SLC5A2 and type 2 diabetes mellitus: Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor drug approved by US Food and Drug Administration (FDA) in 2014 for the treatment of type 2 diabetes (T2DM).